Search results

Sort By:

Limit search:

Squamous cell oesophageal cancer in retinoblastoma survivor: does germinal RB1 mutation influence chemo- and radiosensitivity?

100%

Dworzecki T., Smolska-Ciszewska B., Suwiński R.

OncoReview

2014

vol. 4

issue 2

A72-75

The case of complete response of squamous cell oesophageal cancer to radiochemotherapy in patient previously operated due to hereditary retinoblastoma is presented. Second cancers in retinoblastoma survivors are the main cause of death in that group of patients in developed countries. There is little data on the outcome of treatment in those patients but the few papers available suggest rather poor prognosis. However, it is not clear whether the biology of cancer determined by RB gene mutation is responsible for that. The data suggesting decreased radio- and chemoresistance in cancers with decreased RB gene expression is discussed in the present paper. The role of that gene in the response to cancer treatment was showed in lung, breast and bladder cancer. Moreover, laboratory studies seem to confirm clinical observations and show that RB gene inhibition leads to increased cytotoxic effect of cisplatin, etoposide and 5-fluorouracil. It seems that without the incorporation of gene expression profiling into clinical practice further improvement in cancer treatment will be difficult to achieve.

Identification of serum proteome components associated with progression of non-small cell lung cancer

52%

Pietrowska M., Jelonek K., Michalak M., Roś M., Rodziewicz P., Chmielewska K., Polański K., Polańska J., Gdowicz-Kłosok A., Giglok M., Suwiński R., Tarnawski R., Dziadziuszko R., Rzyman W., Widłak P.

2014

vol. 61

issue 2

325-331

The aim of the present study was to perform comparative analysis of serum from patients with different stages of non-small cell lung cancer (NSCLC) using the three complementary proteomic approaches to identify proteome components associated with the progression of cancer. Serum samples were collected before any treatment from 200 patients with NSCLC, including 103 early stage, 64 locally advanced and 33 metastatic cancer samples, and from 200 donors without malignancy. The low-molecular-weight fraction of serum proteome was MALDI-profiled in all samples. Serum proteins were characterized using 2D-PAGE and LC-MS/MS approaches in a representative group of 30 donors. Several significant differences were detected between serum samples collected from patients with early stage cancer and patients with locally advanced cancer, as well as between patients with metastatic cancer and patients with local disease. Of note, serum components discriminating samples from early stage cancer and healthy persons were also detected. In general, about 70 differentiating serum proteins were identified, including inflammatory and acute phase proteins already reported to be associated with the progression of lung cancer (serum amyloid A or haptoglobin). Several differentiating proteins, including apolipoprotein H or apolipoprotein A1, were not previously associated with NSCLC. No significant differences in patterns of serum proteome components were detected between patients with adenocarcinoma and squamous cell carcinoma. In conclusion, we identified the biomarker candidates with potential importance for molecular proteomic staging of NSCLC. Additionally, several serum proteome components revealed their potential applicability in early detection of the lung cancer.

Refine search results

1 Acta Biochimica Polonica

1 OncoReview

2 2014

2 Suwiński R.

1 Chmielewska K.

1 Dworzecki T.

1 Dziadziuszko R.

1 Gdowicz-Kłosok A.

1 Giglok M.

1 Jelonek K.

1 Michalak M.

1 Pietrowska M.

1 Polańska J.

1 Polański K.

1 Rodziewicz P.

1 Roś M.

1 Rzyman W.

1 Smolska-Ciszewska B.

1 Tarnawski R.

1 Widłak P.

Search results

Squamous cell oesophageal cancer in retinoblastoma survivor: does germinal RB1 mutation influence chemo- and radiosensitivity?

Identification of serum proteome components associated with progression of non-small cell lung cancer